ALX ONCOLOGY HOLDINGS Business Summary

ALX Oncology Holdings Inc. (ALXO) is a clinical-stage biopharmaceutical company that operates on a research-and-development business model, generating value through the advancement of its proprietary immuno-oncology pipeline toward future licensing, milestone payments, and commercial product sales. Currently pre-revenue, the company’s primary segments are centered on its lead candidate, evorpacept (ALX148), a high-affinity CD47 blocker, and ALX2004, a novel EGFR-targeted antibody-drug conjugate (ADC) designed for solid tumors. ALX Oncology operates within a competitive landscape that includes Zymeworks, Rocket Pharmaceuticals, Shattuck Labs, and I-Mab. The company occupies a differentiated market position by utilizing an "Fc-silenced" protein engineering strategy, which enables potent CD47 blockade while minimizing the off-target hematologic toxicities—such as anemia and thrombocytopenia—that have historically limited the clinical utility of competing CD47-targeted therapies. The company was co-founded by Chairman Corey Goodman, Ph.D., a member of the National Academy of Sciences and former Pfizer executive, alongside scientific founder Jaume Pons, Ph.D. The current leadership team is headed by CEO Jason Lettmann, who transitioned from the board in 2023 and previously served as a General Partner at Lightstone Ventures. Key executive roles are held by CFO Harish Shantharam, formerly of Gilead Sciences and CymaBay Therapeutics; COO Allison Dillon, Ph.D., who oversees business and operational strategy; and Interim CMO Barbara Klencke, M.D., a seasoned oncology leader with a background at Sierra Oncology and Genentech. ALX Oncology is supported by a high-pedigree investor base and board that includes representatives from venBio Partners, Lightstone Ventures, Vivo Capital, and Redmile Group.